Takeda Pharmaceutical. has filed a patent for antigen binding agents that target guanylyl cyclase C (GCC). The patent includes nucleic acids, vectors, cells, fragments, and compositions for therapeutic use. Specific sequences for the heavy chain variable region are outlined in the claim. GlobalData’s report on Takeda Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Takeda Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Takeda Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Takeda Pharmaceutical's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies binding to guanylyl cyclase c (gcc) for therapeutic use

Source: United States Patent and Trademark Office (USPTO). Credit: Takeda Pharmaceutical Co Ltd

A patent application (Publication Number: US20240033359A1) discloses a guanylyl cyclase C (GCC) binding agent with specific heavy chain variable region (VH) sequences. The agent includes VH regions with complementarity determining region (CDR) sequences, such as HYYWS, RIYPSGSTSYNPSLKS, and DRSTGWSEWNSDL, among others. These sequences are crucial for the binding agent's effectiveness in targeting GCC. Additionally, the agent comprises immunoglobulin heavy chain variable regions that are at least 90% identical to specific amino acid sequences, ensuring high specificity and efficacy in binding to GCC.

Furthermore, the patent application details methods of treating cancer by administering the GCC binding agent to individuals in need of treatment. The disclosed agent is particularly effective in treating gastrointestinal cancers, including colorectal cancer, stomach cancer, and esophageal cancer. The pharmaceutical composition containing the GCC binding agent and a pharmaceutically acceptable carrier is designed for efficient delivery and treatment. Additionally, the application covers methods of inducing an immune response and cytotoxicity, as well as detecting the presence of cancer in mammals using the GCC binding agent. Overall, the patent application provides a comprehensive overview of the GCC binding agent's potential applications in cancer treatment and detection, highlighting its specificity and efficacy in targeting GCC on cancer cells.

To know more about GlobalData’s detailed insights on Takeda Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies